Anzeige
Mehr »
Login
Freitag, 07.02.2025 Börsentäglich über 12.000 News von 685 internationalen Medien
Die Zukunft ist jetzt: Wie die Robotik-Revolution den US-Aktienmarkt in den Schatten stellt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E4MU | ISIN: US87975F1049 | Ticker-Symbol:
NASDAQ
07.02.25
22:00 Uhr
4,370 US-Dollar
-0,160
-3,53 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TELOMIR PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
TELOMIR PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur TELOMIR PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiTelomir Pharmaceuticals, Inc. - 10-K, Annual Report-
28.01.Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza and Other Viruses134Oxidative stress drives aging and is a key factor in diseases like Alzheimer's, Age-related Macular Degeneration (AMD), cardiovascular diseases, cancer, and diabetes. It also plays a critical role in...
► Artikel lesen
28.01.Telomir touts potential of Telomir-1 in addressing oxidative stress4
28.01.Telomir Pharmaceuticals, Inc. - 8-K, Current Report3
07.01.Telomir Pharmaceuticals confirms lifespan restoration in Progeria preclinical model with Telomir-11
07.01.Telomir Pharmaceuticals, Inc.: Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria184MIAMI, FL / ACCESSWIRE / January 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), an emerging leader in age-reversal science focused on treating the root causes of diseases rather...
► Artikel lesen
TELOMIR PHARMACEUTICALS Aktie jetzt für 0€ handeln
07.01.Telomir Pharmaceuticals, Inc. - 8-K, Current Report1
23.12.24Telomir-1 zeigt vielversprechende Ergebnisse in Kupferbindungsstudien3
23.12.24Telomir-1 shows promise in copper binding studies4
23.12.24Telomir Pharmaceuticals, Inc.: Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease1.526MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company", an emerging leader in age-reversal science, today announced significant findings from its...
► Artikel lesen
23.12.24EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease2
20.12.24Telomir Pharmaceuticals, Inc. - 8-K, Current Report-
12.12.24Telomir Pharmaceuticals secures $1 million equity funding2
12.12.24Telomir Pharmaceuticals, Inc.: Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price217Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth potential. MIAMI, FL / ACCESSWIRE / December 12,...
► Artikel lesen
12.12.24Telomir Pharmaceuticals enters into stock purchase agreement3
11.12.24Telomir Pharmaceuticals, Inc. - 8-K, Current Report-
03.12.24Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?1
03.12.24Telomir-1 zeigt vielversprechende Ergebnisse in präklinischer Diabetes-Studie2
03.12.24Telomir-1 shows promise in diabetes preclinical study1
03.12.24Telomir Pharmaceuticals, Inc.: Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-185Building on preclinical success demonstrating age reversal, longevity, and increased healthspan, Telomir-1 appears to address insulin resistance at its root, achieving reversal to near pre-diabetic...
► Artikel lesen
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1